NCT05278520|Recruiting
Complex Molecular Etiology and Cellular Landscape of Hip Osteoarthritis
OASEQ
Studies on the Complex Molecular Etiology and Cellular Landscape of Hip Osteoarthritis
Loading search results
OASEQ
Studies on the Complex Molecular Etiology and Cellular Landscape of Hip Osteoarthritis
Sponsor study identifier
observational
110
1 country
4
Study Start
January 11, 2023
Actual (reported)Primary Completion
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The purpose of this study is to cast light on the highly complex etiology and cellular landscape of hip osteoarthritis by utilising single-cell and spatial omics.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 3, 2022
Actual (reported)March 14, 2022
Actual (reported)January 11, 2023
Actual (reported)December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Characterization of cell populations in OA
Characterization of cell populations found in different synovial tissues and blood derived samples of OA patients utilising single-cell RNA sequencing solutions.
Starting during the first quarter of 2025, ending by the last quarter of 2026.
Comparison of cell populations between OA cases and controls
The investigators will determine how the cell composition differs between arthritic and corresponding non-arthritic tissues utilising single-cell RNA sequencing solutions.
Starting during the first quarter of 2025, ending by the last quarter of 2026.
Cellular landscape in OA
The investigators will map the transcriptional, regulatory and protein landscape of OA at single-cell and tissue (spatial) level.
Starting during the last quarter of 2024, ending by the last quarter of 2026.
Biomarkers for OA
Starting during the second half of 2026, ending by the last quarter of 2028.
OA endotypes
Starting during the first half of 2025, ending by the second half of 2027.
Fifty adult patients who have hip osteoarthritis.
Forty adult patients who have rheumatoid arthritis in the hip joint.
Twenty adult patients who go through trauma-based emergency total hip arthroplasty and do not have arthritis.
Hip joint replacement surgery. Elective for RA and OA cases.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Adult patients of the HUS (Joint Authority of the Helsinki and Uusimaa Hospital District) Center of Arthroplasty and the Orto Surgical Hospital of Turku University.
PET-centre, University of Turku
Turku, Southwest Finland, Finland
Turku Bioscience, University of Turku
Turku, Southwest Finland, Finland
Turku University Hospital
Turku, Southwest Finland, Finland
Rydgren E, Kotilainen SK, Piipponen M, Lönnberg T, Mikkola L. COMPARISON OF TWO HIGH-RESOLUTION SPATIAL TRANSCRIPTOMICS TECHNOLOGIES TO STUDY SYNOVIAL IMMUNE INFILTRATION IN OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS Osteoarthritis and Cartilage, Volume 33, Issue 6, 2025, page 816. https://doi.org/10.1016/j.joca.2025.03.079
Hip joint synovial tissues and bone, peripheral blood mononuclear cells, serum, plasma, and whole blood.
Lea Mikkola, PhD
Turku Bioscience, University of Turku
First Submitted
March 3, 2022
First Posted
March 14, 2022
Study Start
January 11, 2023
Actual (reported)Primary Completion
December 2028
EstimatedComparison of Clinical Results of Two Cementless Femoral Stem
Key molecular pathways of OA
The investigators will determine what are the key molecular pathways activated in OA.
Starting during the last quarter of 2025, ending by the last quarter of 2027.
Comparison of disease mechanisms between RA and OA
In the Rheumatoid sub-study the investigators will explore the differences in the disease mechanisms between OA and RA by comparing synovial tissues and peripheral blood sample constituents.
Starting during the last quarter of 2024, ending by the last quarter of 2028.
Contact the study team to confirm eligibility.
Helsinki University Hospital
Espoo, Uusimaa, Finland
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
August 24, 2025
Record last verified: 2025-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: